Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SLBT · NASDAQ · Biological Products, (No Diagnostic Substances) · Foreign private issuer
Sl Science Holding (SLBT) · oqro.io/stocks/SLBT · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Sl Science Holding is on record in SEC filings since 2006.
No open-market sale by an insider of Sl Science Holding (SLBT) was filed with the SEC in the last 90 days.
No trade in Sl Science Holding (SLBT) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$0.55−0.0312 (−5.37%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−83.5% (−$2.78) from Jun 15, 2026 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $3.33 on Jun 15, 2026 to $0.55 on Nov 20, 2026 (−83.5%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in Taipei City. Foreign private issuer: reports on Form 20-F or 40-F.
Biological Products, (No Diagnostic Substances) company based in Taipei City. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Last 12 months
Not enough history
Market value
–
Short interest: 50K shares sold short, +36.6% vs the previous count, 1.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
No Schedule 13D or 13G filing on SLBT over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Every annual report has a section where the company's managers explain the year's results (Item 5, Operating and financial review). In this report it runs to about 4,000 words.
SL Bio specializes in developing innovative cellular and gene therapies. It began its business in 2023, and serves as a supplier of animal products to customers in Taiwan. Since June 2024, SL Bio has engaged in research and development in the biomedical industry, including with CD-19 Armed-T products and further extended this research and development to GDT cell therapy products for brain and pancreatic cancers in December 2024. SL Bio was established as the holding company with the intention to perform reorganization of X-Source Future Technology Co., Ltd., a company incorporated in Taiwan in July 2022 (the “Reorganization”). On November 4, 2024, X-Source Future Technology Co., Ltd. changed its name to SL Bio Co., Ltd. (“SL Bio Taiwan”). On May 6, 2022, SL Link Co., Ltd.
And 14 more headings in the filing.
Source: SEC EDGAR, Form 20-F filed Jun 18, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Things to keep in mind
Records
Off-exchange trading: 39.2% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (6.1% on ATS, 33.1% with other brokers), below its 18-week average of 46.8%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (29.4%), IBKR ATS (14.9%), INTELLIGENT CROSS LLC (11.2%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.